Valproate induced hyperammonemic encephalopathy treated by haemodialysis

• Main Authors: Vinay Singh Chauhan, Siddarth Dixit, Sunil Goyal, Sudip Azad
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2017-01-01
• Series: Industrial Psychiatry Journal
• Subjects: Divalproex sodium; encephalopathy; hyperammonemia
• Online Access: http://www.industrialpsychiatry.org/article.asp?issn=0972-6748;year=2017;volume=26;issue=1;spage=99;epage=102;aulast=Chauhan

Valproate (VPA)-induced hyperammonemic encephalopathy is an unusual, but serious, adverse effect of divalproex sodium (DVPX) treatment and if untreated can lead to raised intracranial pressure, seizures, coma, and eventually death. It can, however, be reversed if an early diagnosis is made. It is therefore extremely important to recognize it and discontinue DVPX treatment. Our patient developed sudden deterioration of sensorium, drowsiness, lethargy, and later severe comatose state after few days of starting DVPX with high levels of serum ammonia despite therapeutic levels of VPA and normal liver function test. He responded to hemodialysis, cerebral decongestants, and other intensive supportive measures.